Atrial Fibrillation Clinical Trial
Official title:
Validation of the Advisor HD Grid Mapping Catheter in Atrial Fibrillation Ablation
Verified date | November 2022 |
Source | University of Calgary |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary study concept is to evaluate the superiority of the HD Grid high-density mapping catheter over the current standard 20-pole circular mapping catheter in pulmonary vein isolation (PVI) in atrial fibrillation. A minimum of 20 evaluable subjects with symptomatic atrial fibrillation scheduled for a clinically indicated first PVI ablation will be included.
Status | Completed |
Enrollment | 20 |
Est. completion date | November 1, 2022 |
Est. primary completion date | November 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: 1. Patients with symptomatic paroxysmal or persistent atrial Fibrillation.1 2. Patients referred for a clinically indicated catheter ablation with a plan for PVI only. 3. 18-85 year of age at time of consent. 4. Able and willing to comply with all protocol requirements. 5. Signed patient Informed Consent (ICF). Exclusion Criteria: 1. History of prior left-sided catheter or surgical ablation for AF or atypical atrial flutter, including MAZE or mini MAZE. Prior ablation for typical atrial flutter or left-sided ablation for WPW, AV-node reentry tachycardia or right-sided focal ectopic atrial tachycardia may be included. 2. Planned for left atrial ablation beyond PVI. 3. Uncontrolled heart Failure or NYHA Class III or IV heart failure. 4. Left ventricular ejection fraction < 35 % 5. Left atrial size > 55 mm diameter on echocardiogram. 6. Severe Pulmonary Hypertension 7. Reversible causes of AF (electrolyte imbalance, thyroid disease…) 8. Poor candidate for general anesthesia or deep sedation 9. Anticipated survival < 1 year 10. MI or CABG within 3 months, severe valvular disease 11. Any documented thromboembolic event within 6 months. 12. Contraindication to systemic oral anticoagulation therapy. 13. Significant congenital anomaly or medical condition that may affect the integrity of study data. 14. Women who are pregnant or breastfeeding. 15. Active enrollment in another investigational study involving a drug or device. |
Country | Name | City | State |
---|---|---|---|
Canada | University of Calgary | Calgary | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Calgary |
Canada,
Porterfield C, J Gora P, Wystrach A, Rossi P, Rillo M, A Sebag F, Giuggia M, Mantica M, Dorszewski A, Eldadah Z, Volpicelli M, Bottoni N, Jøns C, T Hollis Z, Dekker L, Mathew S, Schmitt J, Nilsson K. Confirmation of Pulmonary Vein Isolation with High-Density Mapping: Comparison to Traditional Workflows. J Atr Fibrillation. 2020 Apr 30;12(6):2361. doi: 10.4022/jafib.2361. eCollection 2020 Apr-May. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of gaps | The primary endpoint is the mean number of gaps identified per patient identified by the HD Grid catheter after standard PVI procedure with the CMC-20 catheter. | During the ablation procedure. | |
Primary | Location of gaps | The co-primary endpoint is the location of the gaps identified per patient by the HD Grid catheter after standard PVI procedure with the CMC-20 catheter. | During the ablation procedure. | |
Secondary | Per vein analysis for the presence of any gap. | A per vein analysis will be performed for the presence of any gap as a binary outcome. | During the ablation procedure. | |
Secondary | Per vein analysis for the mean number of gaps. | A per vein analysis will be performed for the mean number of gaps. | During the ablation procedure. | |
Secondary | Per pair of veins analysis for the presence of any gap. | A per pair of veins (left and right separately) analysis will be performed for the presence of any gap as a binary outcome. | During the ablation procedure. | |
Secondary | Per pair of veins analysis for the mean number of gaps. | A per pair of veins (left and right separately) analysis will be performed for the mean number of gaps. | During the ablation procedure. | |
Secondary | Mapping time | Left atrial mapping time for both the CMC-20 and the HD Grid catheter | During the ablation procedure. | |
Secondary | Discrepancies | Discrepancies in the prevalence of low voltage areas defined as a voltage <0.50 mV between the CMC-20 and HD Grid catheter in sinus rhythm. | During the ablation procedure. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Terminated |
NCT04115735 -
His Bundle Recording From Subclavian Vein
|
||
Completed |
NCT04571385 -
A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF)
|
Phase 2 | |
Completed |
NCT05366803 -
Women's Health Initiative Silent Atrial Fibrillation Recording Study
|
N/A | |
Completed |
NCT02864758 -
Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
|
||
Recruiting |
NCT05442203 -
Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease
|
N/A | |
Completed |
NCT05599308 -
Evaluation of Blood Pressure Monitor With AFib Screening Feature
|
N/A | |
Completed |
NCT03790917 -
Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
|
||
Enrolling by invitation |
NCT05890274 -
Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO
|
N/A | |
Recruiting |
NCT05316870 -
Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation
|
N/A | |
Recruiting |
NCT05266144 -
Atrial Fibrillation Patients Treated With Catheter Ablation
|
||
Not yet recruiting |
NCT06023784 -
The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Recruiting |
NCT04092985 -
Smart Watch iECG for the Detection of Cardiac Arrhythmias
|
||
Completed |
NCT04087122 -
Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures
|
N/A | |
Completed |
NCT06283654 -
Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
|
||
Recruiting |
NCT05416086 -
iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|
||
Completed |
NCT04546763 -
Study Watch AF Detection At Home
|
||
Completed |
NCT03761394 -
Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke
|
N/A |